New chemo cocktail shows promise in myeloma stem cell transplants
NCT ID NCT01702831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took lenalidomide maintenance after transplant until the disease worsened. The main goal was to see how many patients had no detectable cancer cells (minimal residual disease negativity) 100 days after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Busulfan and melphalan (chemotherapy drugs)
What this could lead to
If successful, this combination could improve the depth of response after stem cell transplant and help keep multiple myeloma under control for longer.
What could go wrong
This is a small, single-arm phase 2 study, so results may not apply broadly. Chemotherapy side effects can be serious, and the disease may still return despite maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cross Cancer Institute 11560 University Ave
Edmonton, Alberta, T6G-1Z2, Canada
-
Hôpital Maisonneuve-Rosemont, 5415, boul. de l'Assomption
Montreal, Quebec, H1T 2M4, Canada
-
London Regional Cancer Program 790 Commissioners Road East
London, Ontario, N6A 4L6, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Queen Elizabeth II Health Sciences Centre.
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Royal Victoria Hospital, MUHC Glen Site, Cedars Cancer Centre
Montreal, Quebec, H4A 3J1, Canada
-
Saint John Regional Hospital, 5DN Research Department, 400 University Ave
Saint John, New Brunswick, E2L 4L2, Canada
-
Saskatoon Cancer Centre 20 Campus Drive
Saskatoon, Saskatchewan, S7N 4H4, Canada
-
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
-
Vancouver General Hospital, Centennial Pavilion, 6th Floor
Vancouver, British Columbia, V5Z 1M9, Canada